ALTABAX
LOE ApproachingNDATOPICALOINTMENT
Approved
Apr 2007
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
4
Data completeness
5/8 — Partial
ALTABAX by Almirall is 12. First approved in 2007.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALTABAX (retapamulin) is a topical antibacterial ointment approved in 2007 that treats skin infections caused by Staphylococcus aureus and Streptococcus pyogenes. It works by selectively inhibiting bacterial protein synthesis at the 50S ribosomal subunit, making it bacteriostatic at therapeutic concentrations. The drug is notable for its unique pleuromutilin mechanism with no cross-resistance to other antibiotic classes.
$0.074MPart D
LOE ApproachingDeclining
5mo to LOEMinimal commercial activity with only 122 Part D claims in 2023; brand team likely scaled down ahead of patent expiry.
Mechanism of Action
12.1 Mechanism of Action ALTABAX is an antibacterial agent [see Clinical Pharmacology (12.4)] . 12.2 Pharmacodynamics In post-hoc analyses of manually over-read 12-lead ECGs from healthy subjects (N = 103), no significant effects on QT/QTc intervals were observed after topical application of…
Worked on ALTABAX at Almirall? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.